



Published in final edited form as:

J Alzheimers Dis. 2024 ; 97(3): 1353–1363. doi:10.3233/JAD-230976.

The Association of Alzheimer’s Disease-related Blood-based Biomarkers with Cognitive Screening Test Performance in the Congolese Population in Kinshasa

Megan Schwinne, M.P.H.^{a,b}, Alvaro Alonso, M.D., Ph.D.^b, Blaine R. Roberts, Ph.D.^c, Sabrina Hickle, Ph.D.^d, Inge MW Verberk, Ph.D.^e, Emmanuel Epenge, M.D.^{f,g}, Guy Gikelekele, M.D.^h, Nathan Tsengele, M.D.^{h,i}, Immaculee Kavugho, M.A.^j, Samuel Mampunza, M.D., Ph.D.^h, Kevin E. Yarasheski, Ph.D.^k, Charlotte E. Teunissen, Ph.D.^e, Anthony Stringer, Ph.D.^d, Allan Levey, M.D., Ph.D.^l, Jean Ikanga, Ph.D.^{d,g}

^aEmory University School of Medicine, Department of Biomedical Informatics, Atlanta, GA, 30322, USA

^bEmory University Rollins School of Public Health, Department of Epidemiology, Atlanta, GA 30322, USA

^cEmory University, School of Medicine, Department of Biochemistry, Department of neurology, Atlanta, GA 30322, USA

^dEmory University School of Medicine, Department of Rehabilitation Medicine, Atlanta, GA 30322, USA

^eAmsterdam University Medical Centers, Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam Neuroscience, Neurodegeneration, Amsterdam University Medical Centers, Vrije Universiteit, 1081 HV Amsterdam, the Netherlands

^fUniversity of Kinshasa and Catholic University of Congo, School of Medicine, Kinshasa, Department of Psychiatry, B.P. 7463 Kinshasa I, Democratic Republic of Congo

^gProtestant University of Congo, Kinshasa, B.P. 4745 Kinshasa II, Democratic Republic of Congo

^hUniversity of Kinshasa, Department of Psychiatry, Kinshasa, B.P. 7463 Kinshasa I, Democratic Republic of Congo

ⁱUniversity of Kikwit, Faculty of Medicine, Democratic Republic of Congo

^jMemory Clinic of Kinshasa, Kinshasa, B.P. 7463 Kinshasa I, Democratic Republic of Congo

^kC₂N Diagnostics, C₂N Diagnostics, Saint Louis, MO 63110, USA

^lEmory University School of Medicine, Department of Neurology, Atlanta, Georgia 30322, USA

***Corresponding author.** Please send general questions about the study to Dr. Jean Ikanga. Jean N. Ikanga, Ph.D., Department of Rehabilitation Medicine, Emory University, 1441 Clifton Rd NE, Atlanta, GA 30322, USA, jikanga@emory.edu, Office Phone: (404) 712-5667.

CONFLICT OF INTEREST

KEY is employed by and receives equity compensation from C₂N Diagnostics, LLC. All other authors have no conflict of interest to report.

Abstract

Background: Alzheimer's Disease (AD), the most common cause of dementia, poses a significant global burden. Diagnosis typically involves invasive and costly methods like neuroimaging or cerebrospinal fluid (CSF) biomarker testing of phosphorylated tau (p-tau) and amyloid- $\beta_{42/40}$ ($A\beta_{42/40}$). Such procedures are especially impractical in resource-constrained regions, such as the Democratic Republic of Congo (DRC). Blood-based biomarker testing may provide a more accessible screening opportunity.

Objective: This study aims to examine if AD-related blood-based biomarkers are associated with cognitive test performance in the Congolese population, where limited research has been conducted.

Methods: In this cross-sectional study of 81 Congolese individuals, cognitive assessments (Alzheimer's Questionnaire (AQ) and Community Screening Interview for Dementia (CSID)) distinguished dementia cases from controls. Blood draws were taken to assess p-tau 181 and $A\beta_{42/40}$ biomarkers. Relationships between the biomarkers and cognitive performance were analyzed using multiple linear regression models.

Results: Lower plasma $A\beta_{42/40}$ was significantly associated with lower CSID scores and higher AQ scores, indicative of AD ($p < 0.001$). These relationships were observed in healthy controls (CSID $p = 0.01$, AQ $p = 0.03$), but not in dementia cases. However, p-tau 181 did not exhibit significant associations with either measure. Factors such as age, sex, education, presence of APOE e4 allele, did not alter these relationships.

Conclusion: Understanding relationships between AD-related screening tests and blood-biomarkers is a step towards utilization of blood-based biomarker tests as a screening tool for AD, especially in resource-limited regions. Further research should be conducted to evaluate blood biomarker test efficacy in larger samples and other populations.

Keywords

Alzheimer's Disease; amyloid-beta protein; biomarkers; blood-based biomarkers; cognitive test; dementia; tau proteins

INTRODUCTION

Dementia, one of the top five causes of death globally, is an umbrella term encompassing a group of characteristic symptoms, which include difficulties with memory, language, problem-solving, and other thinking skills [1,2]. Alzheimer's Disease (AD), the leading cause of dementia in individuals aged 65 or older, is a large global burden, with about 60 million people currently living with dementia¹ and predicted to be over 150 million by 2050 [3,4]. Dementia is a clinical syndrome that does not require a diagnosis via biomarker measurements or PET-scans. However, AD is diagnosed based on clinical symptoms of dementia along with a distinct biomarker profile or PET-scan [5]. AD is a slowly progressive neurodegenerative disease characterized by cerebral accumulation of amyloid plaques and neurofibrillary tangles [4]. The changes in the brain from AD, such as the degeneration of nerve cells as well as the accumulation of the abnormal proteins, beta-amyloid and phosphorylated tau, are contributors to dementia [2]. While the underlying cause of these

pathological changes in AD is still unknown, the predominant risk factor is aging, in which the incidence is higher with increasing age with a late onset of 65 years or older. Genetic factors also play a major role, with 70% of AD cases relating to genetics [4]. In fact, the e4 allele of the apolipoprotein E (APOE) gene is the strongest genetic risk factor for AD and the APOE e2 allele is the strongest genetic protective factor [6].

As AD risk increases with age, it is important to focus on the African population, since they are aging at an unprecedented rate [2,7]. This demographic transition is occurring faster in low and middle-income countries (LMIC) than it was in the previous century for high-income countries (HIC) [8]. Thus, the largest proportion of the predicted increase in AD will take place in LMIC, especially East Asia and Sub-Saharan Africa, where over 70% of individuals with dementia are expected to live in 2040 [7,8].

Common measures to screen for AD and related dementias include the Alzheimer's Questionnaire (AQ) and the Community Screening Interview for Dementia (CSID). These measures combine a short cognitive screener with information from close contacts regarding daily functioning; the combination of the two types of tests yields better sensitivity and specificity for dementia diagnosis [9]. While the two screening tools have some different cognitive domains being tested, they both encompass semantic, executive, and memory knowledge [10]. Since both assessments have different attributes that may be advantageous to different populations, it is important to utilize multiple screening tools and supplementary tactics to identify cases of AD.

Given that neurodegenerative diseases, such as AD, are difficult to diagnose clinically, characteristic biomarkers of AD, such as total tau (T-tau), phosphorylated tau (p-tau), amyloid- β_{42} ($A\beta_{42}$), and amyloid- β_{40} ($A\beta_{40}$), are important for research and early diagnosis [11,12]. Increased levels of T-tau and p-tau with decreased $A\beta_{42}$ in cerebrospinal fluid (CSF) is the biomarker pattern known as the "Alzheimer's CSF Profile", as they reflect key elements of AD pathophysiology [13]. Tau protein normally binds to and stabilizes the neuronal microtubules but hyperphosphorylation disrupts the microtubules, impairs the plasma and axon flow, and leads to loss of neuronal connectivity [13]. A lower $A\beta_{42}$ reflects aggregation and deposition of protein in the brain. $A\beta_{40}$ is the most abundant variant of $A\beta$ in CSF, so the $A\beta_{42/40}$ ratio is utilized to compensate for inter-individual differences in amyloid precursor protein (APP) expression and processing that can result in different but proportional concentrations of the CSF and plasma $A\beta$ peptides. As such, the $A\beta_{42/40}$ ratio is a better predictor of the presence of brain amyloid plaques than the plasma concentrations alone [13,14,15]. Low CSF and plasma $A\beta_{42/40}$ ratios and high tau concentrations are fluid biomarkers for AD pathology [13]. Although obtaining the biomarkers via CSF has been customary practice, obtaining the biomarkers from blood is more accessible than CSF and is preferable for both screening and sampling purposes [13]. While there are several caveats making blood more challenging than CSF for brain biomarkers, such as dilution with other plasma proteins and degradation by proteases in the blood, novel developments in ultrasensitive immunoassays as well as mass spectrometry bring promising results for the use of blood biomarkers over CSF biomarkers [13].

Substantial research has been implemented to demonstrate the use of cognitive tests as well as CSF biomarkers, such as A β _{42/40} and p-tau 181, to screen for AD; however, current research on the association between AD diagnosis and these biomarkers in blood has been predominantly limited to studies conducted in high-income countries. Very few studies have occurred in Sub-Saharan Africa, specifically in the DRC [7,8]. Given the invasiveness and expense of retrieving biomarkers via CSF, it is critical to determine other plausible screening methods to evaluate individuals for AD. Furthermore, with the increasing prevalence of AD in LMIC, in specific Africa, it is important to focus research on these populations, especially since the majority of AD-related research is conducted in populations of European ancestry and in high-income countries. This study aims to evaluate the association between AD-related plasma biomarkers with the cognitive tests, CSID and AQ, in a cohort from Sub-Saharan Africa.

METHODS

Study Design and Participants

From 2019 to 2022, a cross-sectional study using community-based recruitment was carried out in Kinshasa, the capital of the Democratic Republic of Congo (DRC). 1432 individuals were recruited from churches, clinics, hospitals, door-to-door, and older adult associations to then be screened. Eligibility criteria required that participants are 50 years or older, have a close contact to serve as a collateral informant, have no current or past history of neurodevelopmental, mental, psychiatric, or neurodegenerative diagnosis other than dementia, able to give informed consent, fluent in French or Lingala, and have adequate sensory perceptual skills to be able to see and draw for cognitive tests. Cognitive test data was collected between 2019–2021 and blood specimens for biomarker analysis were collected between 2021–2022. Only some participants, less than those who had cognitive tests, were given the option to proceed with donating blood specimens. The enrollment flowchart is presented in Figure 1. This study was approved by the Ethics Committee and Institutional Review Boards of the University of Kinshasa and written informed consent was obtained from participants as well as financial compensation.

Cognitive Measurements

Participants and their informants were administered the CSID as well as the AQ test to screen for dementia and to be further assigned into the dementia group or the healthy control group, which comprised of individuals with normal cognitive aging. The CSID, a 42-question screening measure, provides a score ranging from 0 to 55, with a lower score indicating worse cognition. As a widely accepted dementia screening tool to use cross-culturally, it serves to detect dementia in various populations with diverse educational, cultural, and linguistic identities [7,9]. While this instrument is not the gold standard for diagnosis, it has been used in developing countries when higher quality screening instruments are not available. It evaluates the cognitive domains of language and expression, memory, learning, attention and calculation, praxis, orientation in space and time, and language comprehension. The AQ, an informant-only questionnaire, is 21-questions, with a score ranging from 0 to 26; a higher score indicates worse cognition. It is advantageous in providing questions that require yes or no answers in a weighted format, requiring no

interpretation for individual components of the test [10]. This assessment evaluates the memory, orientation, functional ability, visuospatial, and language domains. Participants were first classified using CSID scores as cognitively impaired (CSID score of < 25.5) or as cognitively unimpaired (CSID score of ≥ 25.5). Next, participants were classified within each category of cognition via AQ scores as cognitively impaired (AQ score of > 13) or as cognitively unimpaired (AQ score of ≤ 13). Given the two cognitive tests and classifications, 4 separate groups were created, which were major neurocognitive disorder (CSID < 25.5 and AQ > 13), mild neurocognitive disorder (CSID < 25.5 and AQ ≤ 13), subjective cognitive impairment (CSID ≥ 25.5 and AQ > 13), and normal cognition (CSID ≥ 25.5 and AQ ≤ 13), following DSM-IV terminology. Only the individuals with major neurocognitive disorder, which were considered to have dementia, and the individuals with normal cognition, which were considered healthy controls, were included for this analysis. Out of the 1432 initial participants, 271 met the above criteria for major neurocognitive disorder or normal cognition, in which 88 individuals were classified as having major neurocognitive disorder and 183 individuals were classified as healthy subjects with normal cognition. Following this classification, an expert panel of neuropsychologists, neurologists, and psychiatrists further evaluated the individuals through neurological and psychiatric evaluations, as well as assessing medical history. They then confirmed 55 individuals to have major neurocognitive disorder and then matched 59 healthy controls on age, education, and sex (Figure 1). Due to the participants not having PET-scans or CSF biomarker tests in this study, participants with major neurocognitive disorder will be characterized as having dementia and will not be identified as individuals with possible AD [5].

Descriptive Measurements

Participants were given self-report questionnaires and interviews to obtain demographic, socioeconomic, and medical history information. Individuals were categorized into age groups of 50–64, 65–74, 75–84, and 85+. Education levels were also categorized into levels of primary school (1–6 years), secondary school (7–12 years), some or completion of university (13–17 years), and beyond university (18+ years). Medical residents measured hypertension by using a manual sphygmomanometer and three measurements of systolic and diastolic blood pressure were collected. Having an average systolic blood pressure over 140 mmHg or a diastolic blood pressure over 90 mmHg was defined as hypertension.

Biomarker Measurements

For the individuals that consented to blood donation for blood biomarker measurements, a phlebotomist drew the blood at the Medical Center of Kinshasa (CMK) blood laboratory by venipuncture into ethylenediaminetetraacetic acid (EDTA) tubes. Blood samples were centrifuged within 15 minutes and 5 ml plasma were aliquoted into 0.5 ml tubes. The samples were temporarily stored at –20 ° Celsius for less than a week and then at –80 ° C for longer-term storage at the CMK laboratory freezer. The samples were then shipped on dry ice to Emory University laboratory and analyzed by C₂N Diagnostics (Aβ₄₂ and Aβ₄₀ peptides) and by Dr. Blaine Roberts's lab at Emory University (p-tau 181). For the Aβ_{42/40} ratios, plasma samples were spiked with stable isotope labeled recombinant proteins. Plasma proteins were extracted using proprietary antibodies conjugated to magnetic beads, eluted from the beads, and then digested with a site-specific protease to form C-terminal peptides

specific to A β ₄₂ and A β ₄₀ proteins. The peptides were separated using micro-flow liquid chromatography and electro-sprayed into the source of a high resolution orbitrap mass spectrometer. This procedure identifies the peptides of interest based on known amino acid sequence and mass to charge ratio. It then quantifies the ion signal intensity from the endogenous peptides by comparison to a calibration curve created with a stable isotope labeled internal standard peptide. The A β ₄₀ and A β ₄₂ concentrations were quantified by comparing the signal intensities for the endogenous peptides to those obtained from the stable isotope labeled proteins spiked into the sample. A β _{42/40} concentration ratios were calculated as plasma A β ₄₂ (pg/mL)/A β ₄₀ (pg/mL). To analyze p-tau 181 concentrations, EDTA plasma samples were prepared according to manufacturer's instructions from the p-tau 181 kit v2 (Quanterix Billerica, Massachusetts, USA). Samples were run in a single path. Plasma was thawed at room temperature for 45 minutes and then centrifuged at 5000xg for 10 minutes. The plasma samples were then diluted four times on bench and measured on the Simoa HDX platform. Mean intraassay coefficients of variation (CV) were below 10%.

Statistical Analysis

Of the study population, 81 individuals had both biomarker and cognitive data (43 dementia cases and 38 healthy controls, Figure 1). Preliminary analysis involved obtaining frequencies and means of sex, age, education level, and basic medical history, for the overall sample population and the two groups of differing neurological status separately. Chi-square test for proportions and two-sample t-tests were utilized to evaluate significant differences between healthy controls and dementia cases. Multiple linear regression models (Table 4, 5) were utilized to analyze associations between cognitive test scores outcome variable) and blood biomarkers (main independent variable). Neurological status was also a primary indicator variable in a model (Table 2) analyzing associations between either cognitive tests or blood biomarkers (outcome variables) with status. Analyses considered the overall CSID and AQ scores, as well as domain-specific scores (executive, semantic, and memory) separately. The biomarkers evaluated were plasma p-tau 181 and A β _{42/40} values. These models analyzed associations overall as well as stratified by neurological status (dementia or healthy control). A β _{42/40} was modeled in 0.01 increments, its standard deviation, to represent more meaningful findings in relation to associations with cognitive test scores. All models controlled for age, sex, and education, as these covariates may be possible confounders and bias the measures of association. The results were expressed as β -coefficients with corresponding 95% confidence intervals. Tests for potential interactions between biomarkers and covariates, including sex, age, education, and APOE status were conducted to understand if these variables significantly affected the relationship between biomarkers and cognitive tests. Tests for interaction involving the variables age and education were assessed on a continuous scale. The presence of the e4 allele in APOE genotypes, a known risk factor for AD, was assessed as a categorical variable, in which individuals were dichotomized as either having the e4 allele or not [6]. All statistical tests were two-sided, and p-values < 0.05 were considered to be statistically significant. All analyses were conducted using SAS version 9.4 statistical software.

RESULTS

Descriptive and Clinical Characteristics of the Sample Population

Baseline characteristics of the 81 individuals, including demographics and medical history, were reported in Table 1. The sample population consisted of 43 dementia cases and 38 healthy controls with a mean age of 73 years (ranging from 50–88 years old). Sex, body mass index, age groups, and education levels were similar between the dementia and control groups, confirming matching was performed appropriately. Regarding medical history, a large proportion of the participants (53%) had hypertension, with more dementia cases having prevalent hypertension compared to the controls (60% and 45% respectively). Additionally, more of the dementia cases (28%) reported alcohol abuse compared to the control group (11%). The remaining relevant medical history and mental conditions, such as high cholesterol, poor nutrition, anxiety, and depression were minimally reported among the sample. The presence of at least one APOE e4 allele, and the specific APOE genotypes, significantly differed between healthy controls and dementia cases ($p=.004$). Overall, the prevalence of e4 allele was higher in dementia cases than healthy controls, with e3/e4 being the more common genotype in this group.

Descriptive Characteristics of Cognitive Tests

Upon comparison of CSID and AQ cognitive test scores between dementia cases and healthy controls (Table 2), all overall scores as well as the semantic, executive, and memory domain scores were significantly different between the two groups ($p < 0.01$). Given that the higher the CSID score, the better the cognition, on average, the healthy controls scored higher in all CSID domains compared to the dementia cases. The CSID memory domain had the largest difference between groups and the CSID semantic domain scores were the least impacted. Furthermore, the healthy control group scored lower on the AQ cognitive test compared to the dementia cases. Again, the AQ memory domain yielded the largest difference and the AQ semantic domain scores yielded the smallest difference between groups.

Descriptive Characteristics of Blood Biomarkers

Average, $A\beta_{40}$, $A\beta_{42}$, $A\beta_{42/40}$ ratio, and p-tau 181 measures are also presented in Table 2. $A\beta_{42/40}$ was significantly higher in the control group compared to the dementia group ($p=0.002$). $A\beta_{40}$ and $A\beta_{42}$ were not significantly different between groups, but the ratio is most clinically relevant as a biomarker for AD pathology. While $A\beta_{42/40}$ was significantly different, analysis of p-tau 181 yielded essentially identical concentrations between the two groups of differing neurological statuses ($p=0.94$).

Association between Cognitive Tests and Biomarkers

Upon exploration of potential associations between blood biomarkers and cognitive test scores among the whole study population, $A\beta_{42/40}$ was strongly associated with both CSID and AQ overall scores ($p<0.001$), while p-tau 181 was not. CSID overall scores and $A\beta_{42/40}$ demonstrated a positive association while AQ overall scores and $A\beta_{42/40}$ demonstrated a negative association. For every 0.01 increase in $A\beta_{42/40}$, on average the CSID overall score was 3.77 points higher, after adjusting for age, sex, and education. Furthermore, for

every 0.01 increase in $A\beta_{42/40}$, on average the AQ overall score was 4.58 points lower (a cognitively better score) after adjustment. $A\beta_{42/40}$ was only significantly associated with the CSID test ($p=0.01$) and the AQ test ($p=0.03$) among the healthy controls and not among the individuals with dementia (Table 4). Potential interaction between biomarkers with covariates, including sex, age, education, and APOE status was assessed. The test for interactions between these variables all resulted in p -values > 0.05 , meaning interaction was not present and these variables did not modify the relationship between cognitive tests and biomarkers.

Cognitive tests were also stratified into their 3 domains, semantic, executive, and memory function (Table 5). Only the CSID semantic domain was associated with p-tau 181 ($p=0.03$), while all other domains were not significantly associated with this biomarker. However, all cognitive test domains were associated with $A\beta_{42/40}$ ($p < 0.001$) except for the CSID semantic domain. For both the CSID and AQ tests, the memory domain had the strongest difference by 0.01 $A\beta_{42/40}$ increments (3.47 and -2.4 respectively), while the semantic domain had the smallest rate of change (0.38 and -0.78 respectively).

DISCUSSION

Major Findings

In a community-based sample from the DRC, we found associations of blood $A\beta_{42/40}$ with CSID and AQ scores, with lower $A\beta_{42/40}$ correlating with a lower CSID score and higher AQ score, which is characteristic of AD and other dementias. These relationships were present for healthy controls but not participants with dementia. However, circulating p-tau 181 was not associated with either cognitive test. Age, sex, education, and presence of the APOE e4 allele, which are known risk factor for AD, did not significantly modify these associations.

Previous research suggests that the use of biomarkers alongside neurocognitive tests is the future of clinical practice, as they aid in early identification of AD and potential for prevention of dementia manifestation or progression [3]. The literature has repeatedly shown that reduced $A\beta_{42/40}$ and increased p-tau is characteristic of AD, and these relationships have commonly been seen in CSF and more recently studied in blood [13,15]. Plasma $A\beta_{42/40}$ had similar results with CSF tests, however, p-tau did not align as clearly and showed a weaker relationship [16]. This supports these present findings since $A\beta_{42/40}$ was associated with tests displaying cognitive impairment in multiple domains, but p-tau was not. With that said, a recent study investigating associations between these plasma biomarkers and their relationship with AD-associated neuroimaging results show that both biomarkers are significantly associated with AD [17].

Memory significantly differs among those with dementia most likely due to pathophysiological changes, such as the accumulation of amyloid-beta and the development of hyperphosphorylated tau protein tangles [3]. This then leads to secretion of neurotoxins and inflammatory factors, resulting in neuronal death in specific brain areas and causes memory impairment.

$A\beta_{42/40}$'s apparent association compared to p-tau 181's insignificant association with cognitive status may be due to the differences in pathophysiological processes between the biomarkers. $A\beta_{42/40}$ is an early, pre-symptomatic index for increased neurotoxicity, amyloidogenicity, as well as disease severity, whereas p-tau 181 may be a more delayed, symptomatic index for tau hyperphosphorylation, neurofibrillary tangles formation, and degenerative axonal loss in the brain [17]. These processes may manifest differently in blood samples compared to CSF samples, differ between individuals, or differ by the tau phosphorylation site (p-tau181, 217, 231, etc.) measured, since the sites may have slightly different temporal patterns over the disease course. Moreover, it is possible that the significant associations of $A\beta_{42/40}$ but not p-tau 181 is due to higher performance of the mass spectrometry $A\beta_{42/40}$ assay compared to the p-tau 181 assay. It is interesting to note that an earlier study among predominantly asymptomatic African Americans showed that plasma $A\beta_{42/40}$ measures were more highly correlated with brain amyloid status (PET and CSF) than the p-tau 181 biomarker [18]. The findings from the current DRC cohort, support this observation, and suggest the possibility that plasma tau biomarkers may need to be interpreted differently in people of African descent vs. non-Hispanic Caucasians. It is also possible that the lack of association between p-tau 181 and cognitive status in this study was due to the small sample size and may not represent a true finding.

While blood is cheaper, less invasive, and more accessible to sample from individuals compared to CSF, there are inevitable caveats to blood biomarker analysis [19]. It is more difficult to reliably measure blood biomarkers that are related to cognitive disorders because the biomarkers are present at lower concentrations in the blood compared to CSF, which is closer to the brain and allows for a free exchange of molecules [13,16,20]. Only a fraction of brain proteins enters the blood stream and biomarker dilution from peripheral sources may occur. Brain proteins released in the blood may be degraded by proteases or metabolized in the liver, leading to potential for varying measurements that may not necessarily be representative of brain or CSF biomarker levels, and thus, cognitive impairment. Lastly, the low levels of brain proteins entering the blood are mixed in a matrix containing high levels of unrelated plasma proteins that need to be cleared from the plasma during sample preparation and may skew results [13]. Nevertheless, advancements in technology have aided in showing the feasibility of measuring blood-based biomarkers more accurately and with clinically meaningful results.

Strengths and Limitations

This study had numerous strengths through the study design, setting, and statistical analyses methods. First, Sub-Saharan Africa, specifically the DRC, is an understudied area for dementia and AD, therefore this research strengthens and adds to knowledge of AD and its associated biomarkers for this population. The research staff were also familiar with the area and the population of interest so there was enhanced partnership and no language barrier. Third, the sample was relatively healthy and varied in age, sex, and education levels. Additionally, multiple cognitive tests (CSID and AQ) as well as an expert panel were utilized to establish and confirm the participants cognitive ability to prevent misclassification. Additionally, dementia cases and healthy controls were matched on age, sex, and education as part of the study design, but these covariates were also

controlled for in analysis, decreasing the possibility of confounding. Lastly, statistical tests prevented further potential bias by confirming there were no outliers or key variables causing interaction.

As with all research studies, there are inevitably limitations. While Sub-Saharan Africa, specifically the DRC is an understudied area, the population within the region lacks variability in race and ethnicity, so there is lack of generalizability to other populations. Additionally, given the location, it is a complicated setting with less access to advanced technology. Variables that may have been risk factors or confounders, such as physical activity and family history were not considered and the sample size of 81 is rather low, decreasing the statistical power. Lastly, there was a discrepancy in the number of questions in this study's CSID test compared to the most common CSID test (36 vs. 42 questions), which decreases comparability.

Conclusions

Understanding the AD-specific blood biomarkers $A\beta_{42/40}$ and p-tau 181 relationships with neurocognitive tests related to AD is a promising next step in the implementation of blood-based biomarkers in order to overcome access and cost barriers, especially in LMIC. Instruments for quantifying blood biomarkers are becoming more sensitive and implementation is increasing. While blood biomarkers are not equivalent to an AD diagnosis yet, they can be utilized as a screening tool before resorting to PET-scan neuroimaging or CSF biomarker analysis. Future studies are needed in which AD-related blood and CSF biomarkers are tested longitudinally from the same individuals for better comparison and further validation. Furthermore, larger studies with greater sample sizes, additional biomarkers, and diversity in races and ethnicities should be employed to increase global generalizability.

ACKNOWLEDGEMENTS

The authors acknowledged the expertise from the Centre Médical de Kinshasa (CMK), who have assisted our study with blood specimen collection, as well as C2N Diagnostics Laboratory for support in plasma biomarker analysis. Additionally, the authors thank Emory Rollins School of Public Health for guidance with data processing and analysis. Furthermore, this research is Supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award # UL1TR002378. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

FUNDING

This study was supported by grants AARG-19-61778701 and P30AG066511-02S1 from the National Institute on Aging. Dr. Alonso was supported by NIH/NHLBI grant K24HL148521 and NIH/NIA grant P30AG066511. C₂N Diagnostics analyses were supported by the NIH (grant No. R44 AG059489), BrightFocus (grant No. CA2016636), The Gerald and Henrietta Rauenhorst Foundation, and the Alzheimer's Drug Discovery Foundation (grant No. GC-201711-2013978).

DATA AVAILABILITY

The data supporting the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical reasons.

REFERENCES

1. GBD 2019 Dementia Forecasting Collaborators (2022) Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. *Lancet Public Health* 7, e105–e125. [PubMed: 34998485]
2. 2022 Alzheimer's disease facts and figures (2022) *Alzheimers Dement* 18, 700–789. [PubMed: 35289055]
3. Tahami Monfared AA, Byrnes MJ, White LA, Zhang Q (2022) Alzheimer's Disease: Epidemiology and Clinical Progression. *Neurol Ther* 11, 553–569. [PubMed: 35286590]
4. Breijyeh Z, Karaman R (2020) Comprehensive Review on Alzheimer's Disease: Causes and Treatment. *Molecules* 25, 5789. [PubMed: 33302541]
5. Dubois B, Villain N, Frisoni GB, Rabinovici GD, Sabbagh M, Cappa S, Benjanin A, Bombois S, Epelbaum S, Teichmann M, Habert MO, Nordberg A, Blennow K, Galasko D, Stern Y, Rowe CC, Salloway S, Schneider LS, Cummings JL, Feldman HH (2021) Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group. *Lancet Neurol* 20, 484–496. [PubMed: 33933186]
6. Serrano-Pozo A, Das S, Hyman BT (2021) APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches. *Lancet Neurol* 20, 68–80. [PubMed: 33340485]
7. Samba H, Guerchet M, Ndamba-Bandzouzi B, Mbelesso P, Lacroix P, Dartigues JF, Preux PM (2016) Dementia-associated mortality and its predictors among older adults in sub-Saharan Africa: results from a 2-year follow-up in Congo (the EPIDEMCA-FU study). *Age Ageing* 45, 681–687. [PubMed: 27230914]
8. Guerchet M, Mbelesso P, Ndamba-Bandzouzi B, Pilleron S, Desormais I, Lacroix P, Aboyans V, Jesus P, Desport JC, Tchalla AE, Marin B, Lambert JC, Clement JP, Dartigues JF, Preux PM (2014) Epidemiology of dementia in Central Africa (EPIDEMCA): protocol for a multicentre population-based study in rural and urban areas of the Central African Republic and the Republic of Congo. *Springerplus* 3, 338. [PubMed: 25045613]
9. Hall KS, Gao S, Emsley CL, Ogunniyi AO, Morgan O, Hendrie HC (2000) Community screening interview for dementia (CSI 'D'); performance in five disparate study sites. *Int J Geriatr Psychiatry* 15, 521–531. [PubMed: 10861918]
10. Sabbagh MN, Malek-Ahmadi M, Kataria R, Belden CM, Connor DJ, Pearson C, Jacobson S, Davis K, Yaari R, Singh U (2010) The Alzheimer's questionnaire: a proof of concept study for a new informant-based dementia assessment. *J Alzheimers Dis* 22, 1015–1021. [PubMed: 20930293]
11. Olsson B, Lautner R, Andreasson U, Öhrfelt A, Portelius E, Bjerke M, Holtta M, Rosen C, Olsson C, Strobel G, Wu E, Dakin K, Petzold M, Blennow K, Zetterberg H (2016) CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. *Lancet Neurol* 15, 673–684. [PubMed: 27068280]
12. Leuzy A, Mattsson-Carlgrén N, Palmqvist S, Janelidze S, Dage JL, Hansson O (2022) Blood-based biomarkers for Alzheimer's disease. *EMBO Mol Med* 14, e14408. [PubMed: 34859598]
13. Blennow K, Zetterberg H (2018) Biomarkers for Alzheimer's disease: current status and prospects for the future. *J Intern Med* 284, 643–663. [PubMed: 30051512]
14. Barthélemy NR, Saef B, Li Y, Gordon BA, He Y, Horie K, Stomrud E, Salvado G, Janelidze S, Sato C, Ovod V, Henson RL, Fagan AM, Benzinger TLS, Xiong C, Morris JC, Hansson O, Bateman RJ, Schindler SE (2023) CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer's disease. *Nat Aging* 3, 391–401. [PubMed: 37117788]
15. Hu Y, Kirmess KM, Meyer MR, Rabinovici GD, Gatsonis C, Siegel BA, Whitmer RA, Apgar C, Hanna L, Kanekiyo M, Kaplow J, Koyama A, Verbel D, Holubasch MS, Knapik SS, Connor J, Contois JH, Jackson EN, Harpstrite SE, Bateman RJ, Holtzman DM, Verghese PB, Fogelman I, Braunstein JB, Yarasheski KE, West T (2022) Assessment of a Plasma Amyloid Probability Score to Estimate Amyloid Positron Emission Tomography Findings Among Adults With Cognitive Impairment. *JAMA Netw Open* 5, e228392. [PubMed: 35446396]
16. Zetterberg H, Burnham SC (2019) Blood-based molecular biomarkers for Alzheimer's disease. *Mol Brain*, 12, 26. [PubMed: 30922367]

17. Chong JR, Ashton NJ, Karikari TK, Tanaka T, Saridin FN, Reilhac A, Robins EG, Nai YH, Vrooman H, Hilal S, Zetterberg H, Blennow K, Lai MKP, Chen CP (2021) Plasma P-tau181 to A β 42 ratio is associated with brain amyloid burden and hippocampal atrophy in an Asian cohort of Alzheimer's disease patients with concomitant cerebrovascular disease. *Alzheimers Dement* 17, 1649–1662. [PubMed: 33792168]
18. Schindler SE, Karikari TK, Ashton NJ, Henson RL, Yarasheski KE, West T, Meyer MR, Kirmess KM, Li Y, Saef B, Moulder KL, Bradford D, Fagan AM, Gordon BA, Benzinger TLS, Balls-Berry J, Bateman RJ, Xiong C, Zetterberg H, Blennow K, Morris JC (2022) Effect of Race on Prediction of Brain Amyloidosis by Plasma A β 42/A β 40, Phosphorylated Tau, and Neurofilament Light. *Neurology* 99, e245–e257. [PubMed: 35450967]
19. O'Bryant SE, Gupta V, Henriksen K, Edwards M, Jeromin A, Lista S, Bazenet C, Soares H, Lovestone S, Hampel H, Montine T, Blennow K, Foroud T, Carillo M, Graff-Radford N, Laske C, Breteler M, Shaw L, Trojanowski JQ, Schupf N, Rissman RA, Fagan AM, Oberoi P, Umek R, Weiner MW, Grammas P, Posner H, Martins R (2015) Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research. *Alzheimers Dement* 11, 549–560. [PubMed: 25282381]
20. Andreasson U, Blennow K, Zetterberg H (2016) Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders. *Alzheimers Dement* 3, 98–102.




Figure 1. Flow Chart of Recruitment Status from those assessed for eligibility at enrollment (n=1432) to the individuals that were allocated to the dementia or control group and analyzed (n=81)

Table 1.

Descriptive Characteristics of the Sample Population, Stratified by Neurological Status

Variable, n (%)	Overall (n = 81)	Healthy Controls (n = 38)	Dementia Cases (n = 43)	p-value
Demographics				
Male	35 (43%)	16 (42%)	19 (44%)	0.85
Body Mass index, kg/m ² *	24.7 (4.3)	24.6 (4.1)	24.8 (4.4)	0.86
Obesity Status				0.09
Underweight (BMI < 18.5)	2 (2%)	2 (5%)	0 (0%)	
Healthy Weight (BMI 18.5, <25)	45 (56%)	18 (47%)	27 (63%)	
Overweight (BMI 25, <30)	22 (27%)	14 (37%)	8 (19%)	
Obese (BMI ≥ 30)	12 (15%)	4 (11%)	8 (19%)	
Age, years *	73.0 (8.0)	71.7 (7.9)	74.0 (8.1)	0.19
Age Groups, years				0.19
50–64	11 (14%)	6 (16%)	5 (12%)	
65–74	29 (36%)	16 (42%)	13 (30%)	
75–84	37 (46%)	16 (42%)	21 (49%)	
85+	4 (5%)	0 (0%)	4 (9%)	
Years of Education *	8.2 (5.4)	9.2 (5.3)	7.3 (5.5)	0.12
Education Level				0.47
Primary School (1–6 years)	8 (10%)	2 (5%)	6 (14%)	
Secondary School (7–12 years)	28 (35%)	12 (32%)	16 (37%)	
Some/Completed University (13–17 years)	27 (33%)	14 (37%)	13 (30%)	
Beyond University (18+ years)	18 (22%)	10 (26%)	8 (19%)	
APOE e4				
Presence of 1 e4 Allele †	40 (50%)	12 (32%)	28 (65%)	0.0036
e2/e4 Genotype	2 (3%)	2 (5%)	0 (0%)	
e3/e4 Genotype	30 (38%)	9 (24%)	21 (49%)	
e4/e4 Genotype	8 (10%)	1 (3%)	7 (16%)	
Medical History				
Hypertension †	43 (54%)	17 (46%)	26 (60%)	0.19
High Cholesterol †	2 (3%)	1 (3%)	1 (2%)	0.94
Poor Nutrition	1 (1%)	0 (0%)	1 (2%)	0.34
Stroke †	2 (3%)	0 (0%)	2 (5%)	0.17
Tobacco Abuse	9 (11%)	5 (13%)	4 (9%)	0.58
Alcohol Abuse	16 (20%)	4 (11%)	12 (28%)	0.0499
Anxiety	5 (6%)	2 (5%)	3 (7%)	0.75
Depression	7 (9%)	2 (5%)	5 (12%)	0.29

* This variable is reported as mean (SD)

† These values may not sum to the total due to missing data

Table 2.

Descriptive Data of Cognitive Tests and Biomarkers, stratified by Neurological Status

Variable, Mean (SD)	Controls (n = 38)	Dementia (n = 43)	Overall (n = 81)	β_1 (95% CI) *	p-value
Cognitive Tests					
CSID					
Overall Score	31.1 (4.2)	19.7 (5.6)	25.0 (7.6)	-11.0 (-13.2, -8.8)	<.001
CSID Semantic Domain Score	9.9 (0.3)	8.7 (1.8)	9.3 (1.5)	-1.2 (-1.8, -0.6)	0.003
CSID Executive Domain Score	14.9 (2.0)	10.0 (3.8)	12.3 (3.9)	-4.6 (-6.0, -3.3)	<.001
CSID Memory Domain Score	20.7 (4.3)	10.6 (5.1)	15.3 (6.9)	-9.9 (-12.0, -7.8)	<.001
AQ Test					
Overall Score	4.3 (5.4)	19.1 (3.9)	12.1 (8.8)	14.7 (12.6, 16.9)	<.001
AQ Semantic Domain Score	0.2 (1.0)	2.3 (1.7)	1.3 (1.7)	2.0 (1.4, 2.7)	<.001
AQ Executive Domain Score	1.4 (1.7)	6.3 (1.8)	4.0 (3.0)	4.8 (4.0, 5.6)	<.001
AQ Memory Domain Score	2.7 (3.0)	10.4 (2.7)	6.8 (4.8)	7.8 (6.5, 9.1)	<.001
Blood Biomarkers					
A $\beta_{42/40}$	0.106 (0.009)	0.099 (0.008)	0.102 (0.009)	-0.006 (-0.009, -0.002)	0.002
A β_{42} , pg/ml	51.0 (10.8)	47.8 (11.8)	49.3 (11.4)	-3.8 (-8.9, 1.4)	0.152
A β_{40} , pg/ml	486.0 (105.1)	483.4 (117.0)	484.6 (111.0)	-11.7 (-62.5, 39.0)	0.647
p-tau 181, ng/ml	1.5 (1.4)	1.6 (1.4)	1.6 (1.4)	0.02 (-0.6, 0.7)	0.939

* Results from linear regression models are adjusted for age, sex, and education.

Table 3.

Assessing Interaction between Biomarkers and Covariates

Test	Biomarker	p-value for Interaction			
		Age	Sex	Education	APOE e4 Allele
CSID Total Score	p-tau 181, ng/ml	0.57	1.00	0.17	0.17
	A $\beta_{42/40}$ [†]	0.76	0.43	0.41	0.27
Overall AQ Score	p-tau 181, ng/ml	0.80	0.21	0.30	0.18
	A $\beta_{42/40}$ [†]	0.45	0.24	0.33	0.07

[†]A $\beta_{42/40}$ is modeled in 0.01 increments.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 4.

Association Between Cognitive Tests and Biomarkers, Overall and Stratified by Neurological Status

Test	Biomarker	Population	β_1 (95% CI) *	p-value
Overall CSID Score	p-tau 181, pg/ml	Overall	-0.63 (-1.99, 0.73)	0.36
		Dementia	-0.95 (-2.44, 0.53)	0.20
		Controls	-0.50 (-1.73, 0.74)	0.42
	A $\beta_{42/40}$ [†]	Overall	3.77 (1.96, 5.58)	<.001
		Dementia	1.89 (0.68, 4.44)	0.14
		Controls	2.08 (0.62, 3.54)	0.01
Overall AQ Score	p-tau 181, pg/ml	Overall	0.97 (-0.65, 2.58)	0.23
		Dementia	0.92 (-0.18, 2.02)	0.10
		Controls	1.01 (-0.63, 2.65)	0.22
	A $\beta_{42/40}$ [†]	Overall	-4.58 (-6.73, -2.43)	<.001
		Dementia	-1.37 (-3.32, 0.59)	0.17
		Controls	-2.24 (-4.28, -0.20)	0.03

* Results from linear regression models are adjusted for age, sex, and education.

[†] A $\beta_{42/40}$ is modeled in 0.01 increments.

Table 5.

Association Between Cognitive Test Domains and Biomarkers

Test	p-tau 181, ng/ml		A β _{42/40} [†]	
	β_1 (95% CI) [*]	p-value	β_1 (95% CI) [*]	p-value
CSID				
Overall Score	-0.63 (-2.0, 0.7)	0.36	3.77 (2.0, 5.6)	<.001
Semantic Domain Score	-0.30 (-0.6, -0.02)	0.03	0.38 (-0.01, 0.8)	0.06
Executive Domain Score	-0.51 (-1.2, 0.2)	0.15	1.78 (0.9, 2.7)	<.001
Memory Domain Score	-0.20 (-1.5, 1.1)	0.75	3.47 (1.8, 5.1)	<.001
AQ				
Overall Score	0.97 (-0.6, 2.6)	0.23	-4.58 (-6.7, -2.4)	<.001
Semantic Domain Score	0.20 (-0.1, 0.5)	0.23	-0.78 (-1.2, -0.3)	<.001
Executive Domain Score	0.29 (-0.3, 0.8)	0.29	-1.27 (-2.0, -0.5)	0.001
Memory Domain Score	0.39 (-0.5, 1.3)	0.39	-2.4 (-3.7, -1.2)	<.001

* Results from linear regression models are adjusted for age, sex, and education.

[†]A β _{42/40} is modeled in 0.01 increments.